collection
MENU ▼
Read by QxMD icon Read
search

CA19-9 Usefullness

shared collection
3 papers 0 to 25 followers CA 19-9: Biochemical and Clinical Aspects. ScarĂ  S, et al. Adv Exp Med Biol. 2015. Show full citation Abstract CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis a antigen) is the most commonly used and best validated serum tumor marker for pancreatic cancer diagnosis in symptomatic patients and for monitoring therapy in patients with pancreatic adenocarcinoma. Normally synthesized by normal human pancreatic and biliary ductal cells and by gastric, colon, endometrial and salivary epithelia, CA 19-9 is present in small amounts in serum, and can be over expressed in several benign gastrointestinal disorders. Importantly, it exhibits a dramatic increase in its plasmatic levels during neoplastic disease. However, several critical aspects for its clinical use, such as false negative results in subjects with Lewis (a-b-) genotype and false positive elevation, occasional and transient, in patients with benign diseases, together with its poor positive predictive value (72.3 %), do not make it a good cancer-specific marker and renders it impotent as a screening tool. In the last years a large number of putative biomarkers for pancreatic cancer have been proposed, most of which is lacking of large scale validation. In addition, none of these has showed to possess the requisite sensitivity/specificity to be introduced in clinical use. Therefore, although with important limitations we well-know, CA 19-9 continues being the only pancreatic cancer marker actually in clinical use. PMID 26530370 [PubMed - in process] Full text Full text at journal site Similar articles Role of tumour markers, cytogenetics. Review article Lamerz R, et al. Ann Oncol. 1999. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. Ballehaninna UK, et al. J Gastrointest Oncol. 2012. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Ballehaninna UK, et al. Indian J Surg Oncol. 2011. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Kawa S, et al. Br J Cancer. 1991. CA 50: a tumor marker for gastrointestinal malignancies. Review article Bunworasate U, et al. J Med Assoc Thai. 1995. See all
https://www.readbyqxmd.com/read/26788078/pulmonary-manifestations-of-inflammatory-bowel-disease
#1
Sebastian Majewski, Wojciech Piotrowski
Bronchopulmonary signs and symptoms are examples of variable extraintestinal manifestations of the inflammatory bowel diseases (IBD). These complications of Crohn's disease (CD) and ulcerative colitis (UC) seem to be underrecognized by both pulmonary physicians and gastroenterologists. The objective of the present review was to gather and summarize information on this particular matter, on the basis of available up-to-date literature. Tracheobronchial involvement is the most prevalent respiratory presentation, whereas IBD-related interstitial lung disease is less frequent...
December 10, 2015: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/26603829/the-importance-of-surgical-margins-in-pancreatic-cancer
#2
REVIEW
Cecilia G Ethun, David A Kooby
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with a grim prognosis. Surgical resection offers the best chance for long-term survival, yet recurrence rates are high and outcomes are poor. The influence of margin status in PDAC is controversial, as conflicting data have been plagued by a lack of standardization in margin definitions, pathologic analysis, and reporting. Despite recent efforts, international consensus is still needed for this disease.
March 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/26576628/diagnostic-accuracy-of-serum-ca19-9-in-patients-with-cholangiocarcinoma-a-systematic-review-and-meta-analysis
#3
REVIEW
Bin Liang, Liansheng Zhong, Qun He, Shaocheng Wang, Zhongcheng Pan, Tianjiao Wang, Yujie Zhao
BACKGROUND Cholangiocarcinoma (CCA) is a relatively rare cancer worldwide; however, its incidence is extremely high in Asia. Numerous studies reported that serum carbohydrate antigen 19-9 (CA19-9) plays a role in the diagnosis of CCA patients. However, published data are inconclusive. The aim of this meta-analysis was to provide a systematic review of the diagnostic performance of CA19-9 for CCA. MATERIAL AND METHODS We searched the public databases including PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure (CNKI), and WANFANG databases for articles evaluating the diagnostic accuracy of serum CA19-9 to predict CCA...
2015: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"